-
AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis
•
The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical industry, opening up diverse application scenarios for AI + healthcare. IVD companies are leveraging AI-empowered products and services to reduce costs and increase efficiency. New algorithms are helping to speed up the integration and application…
-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced an unsuccessful market filing for its BRCA1/2 gene mutation detection kit, which utilizes the combined probe anchored polymerization sequencing method. The company cited the failure to complete the required complement and correction of information as…
-
BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit
•
BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced the approval of its medical device license from the National Medical Products Administration (NMPA) for a novel gene methylation detection kit. The kit employs fluorescence PCR technology to assess the combined methylation status of the…
-
MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications
•
China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements with eight companies to develop applications based on the G99 sequencing platform. The financial details of these agreements have not been disclosed. DNBSEQ-G99: A Miniaturized Sequencing PlatformDNBSEQ-G99, launched by MGI Tech, is a miniaturized dual…
-
Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population
•
Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive study analyzing genetic data from a large Chinese population, shedding light on genetic risk factors for diseases such as diabetes, stroke, depression, and chronic respiratory disease. The study aims to provide valuable data for drug…
-
BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy
•
China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of understanding (MOU) with Thailand’s Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Genomics Innovation Public Company Limited, and Hemogen Hongkong Alpha Technology., Ltd. The collaboration aims to enhance the prevention and treatment of Thalassemia and…
-
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
•
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of…
-
BGI Genomics Receives ANVISA Approval for Colorectal Cancer Detection Kit
•
China-based genomics giant BGI Genomics Co., Ltd (SHE: 300676) has reported receiving product approval from Brazil’s National Health Surveillance Agency (ANVISA) for its colorectal cancer (CRC) early detection real-time PCR product. The diagnostic kit, used for the auxiliary diagnosis of CRC, is a non-invasive product that detects human genes SDC2,…
-
BGI Genomics Receives NMPA Approval for Chromosome Aneuploidy Detection Kit
•
China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its chromosome aneuploidy detection kit (combined probe anchoring polymerization sequencing method). This marks a significant milestone in the company’s efforts to advance…
